Neoadjuvant Nivolumab with or without Relatlimab in Resectable Non-Small-Cell Lung Cancer: A Randomized Phase II Trial

In this ongoing, open-label Phase II study, 60 biomarker-unselected, treatment-naive patients with resectable NSCLC were randomized to receive two preoperative doses of nivolumab with or without relatlimab antibody therapy.